Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of the American Society of Nephrology

• Publication date

  2005-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1681/ASN.2005010001PMID 15917336
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats.

  2004cited by this paper
• Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

  2004cited by this paper
• Anti‐proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes

  2004cited by this paper
• The involvement of growth hormone (GH), insulin-like growth factors (IGFs) and vascular endothelial growth factor (VEGF) in diabetic kidney disease.

  2004cited by this paper
• Pentoxifylline Ameliorates Renal Tumor Necrosis Factor Expression, Sodium Retention, and Renal Hypertrophy in Diabetic Rats

  2004cited by this paper
• Cellular responses to protein overload: key event in renal disease progression

  2004cited by this paper
• NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy.

  2004cited by this paper
• Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes.

  2003cited by this paper
• Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes.

  2003cited by this paper
• Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.

  2003cited by this paper
• Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study.

  2003cited by this paper
• Combination of Pentoxifylline with Angiotensin Converting Enzyme Inhibitors Produces an Additional Reduction in Microalbuminuria in Hypertensive Type 2 Diabetic Patients

  2003influential reference
• Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats.

  2003cited by this paper
• Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study.

  2003cited by this paper
• Progression of diabetic nephropathy.

  2003influential reference
• Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

  2003cited by this paper
• Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus.

  2003cited by this paper
• [Diabetic nephropathy. A matter of inflammation?].

  2003cited by this paper
• Pentoxifylline attenuated the renal disease progression in rats with remnant kidney.

  2002cited by this paper
• Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

  2002cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• Beneficial Effects of Pentoxifylline in Patients With Idiopathic Dilated Cardiomyopathy Treated With Angiotensin-Converting Enzyme Inhibitors and Carvedilol: Results of a Randomized Study

  2001cited by this paper
• Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFα monoclonal antibody and by pentoxiphylline

  2001cited by this paper
• Prevention of end-stage renal disease due to type 2 diabetes.

  2001cited by this paper
• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

  2001cited by this paper
• Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats.

  2000cited by this paper
• Relation of serum total sialic acid concentrations with diabetic complications and cardiovascular risk factors in Kuwaiti Type 2 diabetic patients.

  2000cited by this paper
• Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes.

  2000cited by this paper
• Diabetes in New Zealand.

  2000cited by this paper
• Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study.

  2000cited by this paper
• American Diabetes Association Annual Meeting, 1999: more on cardiovascular disease.

  2000cited by this paper
• Renoprotective therapy: titration against urinary protein excretion.

  1999cited by this paper
• A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

  1999cited by this paper
• Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals.

  1999cited by this paper
• Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-α and inducible nitric oxide synthase in diabetic rat glomeruli

  1999cited by this paper
• Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration.

  1999influential reference
• Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis.

  1999cited by this paper
• Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus.

  1998cited by this paper
• Pathophysiology of progressive nephropathies.

  1998cited by this paper
• Reduction of Macroalbuminuria With Pentoxifylline in Diabetic Nephropathy: Report of three cases

  1998cited by this paper
• Renoprotection in diabetes: genetic and non-genetic risk factors and treatment

  1998cited by this paper
• TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide.

  1998cited by this paper
• Increased Expression of Intercellular Adhesion Molecule-1 (ICAM-1) in Diabetic Rat Glomeruli: Glomerular Hyperfiltration Is a Potential Mechanism of ICAM-1 Upregulation

  1997cited by this paper
• Understanding the nature of renal disease progression.

  1997cited by this paper
• Effects of pentoxifylline on renal function and blood pressure in cardiac transplant recipients: a randomized trial.

  1997cited by this paper
• Role of glomerular mechanical strain in the pathogenesis of diabetic nephropathy.

  1997cited by this paper
• Effects of pentoxifylline on hemodynamics and oxygenation in septic and nonseptic patients.

  1997cited by this paper
• Raised Serum Sialic Acid Concentration in NIDDM Patients With and Without Diabetic Nephropathy

  1996cited by this paper
• Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients.

  1995cited by this paper
• Cellular events in the evolution of experimental diabetic nephropathy.

  1995cited by this paper
• Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment

  1994cited by this paper
• mRNA Expression of Growth Factors in Glomeruli From Diabetic Rats

  1993cited by this paper
• Pentoxifylline in management of proteinuria in diabetic nephropathy.

  1993cited by this paper
• Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy.

  1991cited by this paper
• Pentoxifylline suppression of tumor necrosis factor gene transcription.

  1991cited by this paper
• Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway

  1990cited by this paper
• Dose‐response effects of pentoxifylline on erythrocyte filterability: Clinical and animal model studies

  1990cited by this paper
• Renal handling and metabolism of adenosine in diabetic rats.

  1989cited by this paper
• Tumor necrosis factor induces glomerular damage in the rabbit.

  1989cited by this paper
• Pentoxifylline, albumin excretion rate and proteinuria in type I and type II diabetic patients with microproteinuria. Results of a short-term randomized study

  1986cited by this paper
• Microalbuminuria: an early marker of renal involvement in diabetes.

  1985cited by this paper
• Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy.

  1983cited by this paper

• Emerging therapeutic pipelines on kidney fibrosis: challenges in translational research.

  2026cites this paper
• The effect of a methylxanthine vasodilator: pentoxifylline on the treatment of diabetic nephropathy—a meta-analysis

  2023influential citation
• Antioxidants for adults with chronic kidney disease.

  2023cites this paper
• Immunomodulatory and Antioxidant Effects of Pentoxifylline and Other Therapeutic Agents in The Management of Myocardial Injury

  2023cites this paper
• Stem cell-derived exosomal MicroRNAs: Potential therapies in diabetic kidney disease.

  2023cites this paper
• Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities.

  2022cites this paper
• Effects of Pentoxifylline on Serum Markers of Diabetic Nephropathy in Type 2 Diabetes

  2022cites this paper
• A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19

  2022influential citation
• Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease

  2022cites this paper
• Targeting inflammation to treat diabetic kidney disease: the road to 2030.

  2022cites this paper
• Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease

  2022cites this paper
• Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications

  2021cites this paper
• Are the Protean Effects of Pentoxifylline in the Therapy of Diabetes and Its Complications Still Relevant?

  2021cites this paper
• Novel Anti-inflammatory and Anti-fibrotic Agents for Diabetic Kidney Disease-From Bench to Bedside.

  2021cites this paper
• The Uses of Pentoxifylline in Nephrology

  2021cites this paper
• Recent advances in drug discovery for diabetic kidney disease

  2020cites this paper
• The Randomized Clinical Trial of Pentoxifylline for Reduction of Blood Pressure in Patients with Primary Hypertension

  2020cites this paper
• Inflammatory Targets in Diabetic Nephropathy

  2020cites this paper
• Clinical burden of autosomal dominant polycystic kidney disease

  2020influential citation
• Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?

  2020cites this paper
• Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets

  2020cites this paper
• Emerging Therapies

  2020cites this paper
• Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19

  2020cites this paper
• Potential drug–drug interactions associated with clinical and laboratory findings at hospital admission

  2019cites this paper
• Pentoxifylline and nephroprotection: effects on renal dysfunction and cardiovascular risks.

  2019cites this paper
• Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons

  2019cites this paper
• Efecto de la pentoxifilina sobre la proteinuria de rango nefrótico en glomerulopatías y nefropatía crónica del injerto. Resultados a los 6 meses de tratamiento

  2019cites this paper
• Berberine and Pentoxifylline: A novel combination in amelioration of acute kidney injury.

  2019cites this paper
• Towards Better Drug Repositioning: Targeted Immunoinflammatory Therapy for Diabetic Nephropathy.

  2019cites this paper
• Exploring macrophage cell therapy on Diabetic Kidney Disease

  2018cites this paper
• Acute Kidney Injury and Progression of Diabetic Kidney Disease.

  2018cites this paper
• Oxidative Stress, Apoptosis, and Mitochondrial Function in Diabetic Nephropathy

  2018cites this paper
• Pentoxyfilline Effect on Reduction of Proteinuria to PATIENTS With Diabet Type-2

  2018cites this paper
• 12 Antioxidant Therapy for Diabetic Kidney Disease

  2017cites this paper
• Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis

  2017influential citation
• The Effect of Pentoxifylline in Reducing Proteinuria in Patients with Diabetic Nephropathy Treated with ACEI or ARB

  2017cites this paper
• Multi-glycoside of Tripterygium wilfordii Hook. f. attenuates glomerulosclerosis in a rat model of diabetic nephropathy by exerting anti-microinflammatory effects without affecting hyperglycemia

  2017cites this paper
• Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update

  2017cites this paper
• Proteinuria in Nondiabetic Patients: Clinical Significance

  2016cites this paper
• A comparison of the postoperative analgesic effects of intravenous dexmedetomidine with a combination of dexmedetomidine and bupivacaine wound infiltration for lower segment cesarean section: A prospective, randomized study

  2016cites this paper
• Pathophysiology of Diabetic Nephropathy

  2016cites this paper
• Effects of pentoxifylline on inflammatory markers and blood pressure: a systematic review and meta-analysis of randomized controlled trials

  2016influential citation
• Established and Emerging Strategies in the Treatment of Chronic Kidney Disease.

  2016cites this paper
• Effect of pentoxifylline in proteinuric chronic kidney disease: a systematic review and meta-analysis

  2016influential citation
• Can Pentoxifylline be used as Adjunct Therapy to ACE Inhibitors and ARBs in Preserving Kidney Function?

  2016cites this paper
• Ameliorative effects of pentoxifylline on NOS induced by diabetes in rat kidney

  2016cites this paper
• Effect of pentoxifylline on renal outcomes in chronic kidney disease patients: A systematic review and meta-analysis.

  2016cites this paper
• Pentoxifylline reduces the inflammatory process in diabetic rats: relationship with decreases of pro-inflammatory cytokines and inducible nitric oxide synthase

  2015cites this paper
• Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study

  2015cites this paper
• Targeting Inflammation Through a Physical Active Lifestyle and Pharmaceuticals for the Treatment of Type 2 Diabetes

  2015cites this paper
• Inhibition of inflammatory cytokines - potential new treatment for diabetic nephropathy

  2015cites this paper
• Pentoxifylline Attenuates Proteinuria in Anti-Thy1 Glomerulonephritis via Downregulation of Nuclear Factor-κB and Smad2/3 Signaling

  2015cites this paper
• Chronic kidney disease among overweight and obesity with and without metabolic syndrome in an urban Chinese cohort

  2015cites this paper
• Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.

  2015cites this paper
• Pentoxifylline Decreases Dialysis Risk in Patients With Advanced Chronic Kidney Disease

  2015cites this paper
• Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs?

  2015cites this paper
• Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis

  2015cites this paper
• Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.

  2015cites this paper
• Inflammatory Cytokines in Diabetic Nephropathy

  2015cites this paper
• Evaluation and Management of Proteinuria After Kidney Transplantation

  2015cites this paper
• Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets

  2015cites this paper
• Effect of Pentoxifylline on Microalbuminuria in Diabetic Patients: A Randomized Controlled Trial

  2015cites this paper
• Add-on Protective Effect of Pentoxifylline in Advanced Chronic Kidney Disease Treated with Renin-Angiotensin-Aldosterone System Blockade - A Nationwide Database Analysis

  2015cites this paper
• Pentoxifylline (PTF) and Kidney

  2015cites this paper
• Emerging Therapies for Chronic Kidney Disease

  2015cites this paper
• Inflammation in diabetic kidney disease.

  2014cites this paper
• Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial

  2014cites this paper
• Targeting inflammation in diabetes: Newer therapeutic options.

  2014cites this paper
• Diabetic kidney disease: from physiology to therapeutics

  2014cites this paper
• Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease.

  2014cites this paper
• TNF-α mediates increased susceptibility to ischemic AKI in diabetes.

  2013cites this paper
• Chemokines and macrophage migration inhibitory factor in diabetic nephropathy

  2013cites this paper
• TNF- (cid:1) mediates increased susceptibility to ischemic AKI in diabetes

  2013cites this paper
• Effect of Add-on Pentoxifylline on Proteinuria in Membranous Glomerulonephritis: A 6-month Placebo-controlled Trial

  2013cites this paper
• Emerging drugs for managing kidney disease in patients with diabetes

  2013cites this paper
• Effects of Losartan and Pentoxifylline on Renal Dimethylarginine Dimethylaminohydrolase-1 Expression in Proteinuric Nephropathy

  2013cites this paper
• Diabetic kidney disease: new treatment options

  2013cites this paper
• Inflammation and Oxidative Stress in Diabetic Nephropathy: New Insights on Its Inhibition as New Therapeutic Targets

  2013cites this paper
• Implications of treatment that target protective mechanisms against diabetic nephropathy.

  2012cites this paper
• Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial.

  2012cites this paper
• New options and perspectives for proteinuria management after kidney transplantation.

  2012cites this paper
• Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.

  2012cites this paper
• Diseases of Renal Parenchyma 204 vascular dysfunction can precede the onset of proteinuria in diabetes

  2012cites this paper
• Pentoxifylline for diabetic kidney disease.

  2012cites this paper
• Cytokines in diabetic nephropathy.

  2012cites this paper
• The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial.

  2012cites this paper
• 2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials.

  2012cites this paper
• The Renin-Angiotensin-Aldosterone System in Renal and Cardiovascular Disease and the Effects of its Pharmacological Blockade

  2012cites this paper
• Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy.

  2012cites this paper
• Antioxidant Therapy for Diabetic Kidney Disease

  2012cites this paper
• Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results.

  2011cites this paper
• Efficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients.

  2011cites this paper
• Evolution of Treatment for Diabetic Nephropathy: Historical Progression from RAAS Inhibition and Onward

  2011cites this paper
• Investigating the significance of relaxin in experimental diabetic renal disease

  2011cites this paper
• Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy

  2011cites this paper
• A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria.

  2011influential citation
• Tratamiento de la nefropatía diabética: más allá del bloqueo del sistema renina-angiotensina

  2011cites this paper
• New approaches to the treatment of nephropathy in diabetes

  2011cites this paper
• Role of oxidative stress in diabetic kidney disease.

  2010cites this paper
• Prolonged Administration Enhances the Renoprotective Effect of Pentoxifylline via Anti-Inflammatory Activity in Streptozotocin-Induced Diabetic Nephropathy

  2010cites this paper